Muromonab-CD3 (brand name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant medication given to reduce acute rejection in people with...
13 KB (1,169 words) - 19:22, 17 July 2024
antibodies reducing the effectiveness of muromonab-CD3. Muromonab-CD3 can cause excessive immunosuppression. Although CD3 antibodies act more specifically than...
29 KB (3,337 words) - 00:02, 9 August 2024
anti-CD3 monoclonal antibody is one that binds to CD3 on the surface of T cells. They are immunosuppresive drugs. The first to be approved was muromonab-CD3...
2 KB (201 words) - 10:11, 10 December 2021
Medicine Nobel Prize for their discovery together with Niels Kaj Jerne. Muromonab-CD3 was the first monoclonal antibody to be approved for clinical use in...
38 KB (3,088 words) - 05:02, 8 August 2024
activate the immune system through receptors on white blood cells. Muromonab-CD3, an anti-CD3 monoclonal antibody intended to suppress the immune system to...
24 KB (2,551 words) - 01:16, 25 June 2024
Retrieved 3 January 2023. Wilde, Michelle I.; Goa, Karen L. (1 May 1996). "Muromonab CD3". Drugs. 51 (5): 865–894. doi:10.2165/00003495-199651050-00010. ISSN 1179-1950...
135 KB (4,054 words) - 22:35, 2 July 2024
lymphoproliferative disorder. Such antibodies include ATG, ALG and OKT3 (muromonab-CD3).[citation needed] Polyclonal PTLD may form tumor masses and present...
8 KB (907 words) - 05:26, 5 July 2024
won the Nobel Prize for Medicine in 1984 for their work. Soon after, muromonab-CD3 became the first fully licensed monoclonal antibody in 1986 for its...
28 KB (3,327 words) - 19:25, 25 July 2024
L04AF06 Peficitinib L04AF07 Deucravacitinib L04AF08 Ritlecitinib L04AG01 Muromonab-CD3 L04AG02 Efalizumab L04AG03 Natalizumab L04AG04 Belimumab L04AG05 Vedolizumab...
3 KB (367 words) - 15:37, 25 January 2024
murabutide (INN) muraglitazar (USAN) murocainide (INN) murodermin (INN) muromonab-CD3 monoclonal antibody (INN) MUSE (brand name for Prostaglandin E1) Mustargen...
2 KB (245 words) - 06:43, 1 June 2024
IL-23 Lebrikizumab Ustekinumab IL-17A Secukinumab Cellular target CD3 Muromonab-CD3 Otelixizumab Teplizumab Visilizumab CD4 Clenoliximab Keliximab Zanolimumab...
7 KB (299 words) - 13:45, 27 April 2024
1 syndrome – multiple myeloma – multiple sclerosis – multiplicity – muromonab-CD3 monoclonal antibody – musculoskeletal – mycophenolate mofetil – mycosis...
69 KB (5,119 words) - 11:20, 3 June 2024
224 – antibodies, monoclonal MeSH D12.776.124.486.485.114.224.570 – muromonab-cd3 MeSH D12.776.124.486.485.114.240 – antibodies, neoplasm MeSH D12.776...
43 KB (3,780 words) - 16:51, 9 February 2024
TRB@ / TRD@ / TRG@ Co-receptors CD8 (CD8α / CD8β) CD4 Accessory molecules CD3 Subunits - one CD3γ / one CD3δ / two CD3ε ζ-chain (CD247, CD3ζ, TCRζ) Pattern...
38 KB (2,656 words) - 12:11, 30 October 2023
224 – antibodies, monoclonal MeSH D12.776.377.715.548.114.224.570 – muromonab-cd3 MeSH D12.776.377.715.548.114.240 – antibodies, neoplasm MeSH D12.776...
133 KB (7,397 words) - 16:43, 9 February 2024
therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986. This drug found use in solid organ...
57 KB (4,072 words) - 11:12, 5 August 2024